Home Cart Sign in  
Chemical Structure| 1032350-13-2 Chemical Structure| 1032350-13-2
Chemical Structure| 1032350-13-2

MK-2206 2HCl

CAS No.: 1032350-13-2

MK-2206 2HCl is a selective AKT inhibitor with IC50 values of 8 nM, 12 nM, and 65 nM for AKT1, AKT2, and AKT3, respectively. MK-2206 2HCl exhibits antitumor effects and is used in research on cancers related to the PI3K/AKT signaling pathway.

Synonyms: MK-2206 (2HCl); MK-2206 (hydrochloride); MK-2206 dihydrochloride

4.5 *For Research Use Only !

Cat. No.: A145592 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łÇó¶ÊÊ Inquiry Inquiry
10mg łÍď¶ÊÊ Inquiry Inquiry
100mg łÇďî¶ÊÊ Inquiry Inquiry
250mg ł§Êò¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1mg

    łÇó¶ÊÊ

  • 10mg

    łÍď¶ÊÊ

  • 100mg

    łÇďî¶ÊÊ

  • 250mg

    ł§Êò¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of MK-2206 2HCl

CAS No. :1032350-13-2
Formula : C25H23Cl2N5O
M.W : 480.39
SMILES Code : O=C1NN=C2C3=C(N=C(C4=CC=C(C5(N)CCC5)C=C4)C(C6=CC=CC=C6)=C3)C=CN21.[H]Cl.[H]Cl
Synonyms :
MK-2206 (2HCl); MK-2206 (hydrochloride); MK-2206 dihydrochloride
MDL No. :MFCD14584463

Safety of MK-2206 2HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of MK-2206 2HCl

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • Akt3

    Akt3, IC50:65 nM

  • Akt1

    Akt1, IC50:8 nM

  • Akt2

    Akt2, IC50:12 nM

In Vitro:

Cell Line
Concentration Treated Time Description Reference
TBD0220 cells 5 μM 24 h Inhibited AKT phosphorylation, reduced the expression of ACSS3, ACSL3, and ELOVL2 PMC10693308
U-87 MG cells 5 μM 24 h Inhibited AKT phosphorylation, reduced the expression of ACSS3, ACSL3, and ELOVL2 PMC10693308
vascular smooth muscle cells (VSMCs) 5 µM 24 h MK-2206 significantly inhibited ADP βs-induced lipid deposition and prevented the decrease in cholesterol efflux by inhibiting the PI3K-AKT signaling pathway. PMC8078663
LNCaP cells 5 μM To assess the resistance of LNCaP cells to MK-2206, it was found that MK-2206-resistant cells (M-R) displayed substantial resistance specifically to MK-2206. PMC9019088
Ba/F3 cells 20 μM 4 days To assess the resistance of AKT1 W80R mutation to MK-2206, it was found that AKT1 W80R mutation significantly increased resistance to MK-2206. PMC9019088

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
BALB/C nude mice GBM orthotopic model Oral 100 mg/kg Once daily for 7 days Inhibited tumor growth and prolonged survival PMC10693308
Mice Laser-induced choroidal neovascularization model Intravitreal injection 10 mM × 2 μL/eye Immediately after laser injury and 1 week later To investigate the effect of MK-2206 on pericyte proliferation and subretinal fibrosis in a laser-induced choroidal neovascularization model, results showed that MK-2206 significantly reduced the areas of PDGFR β and α-SMA positive lesions. PMC9166792
Mice LNCaP prostate cancer xenograft model Oral 25 mg/kg Once daily for 21 days To evaluate the antitumor effect of MK-2206 in the LNCaP xenograft model, it was found that MK-2206 significantly inhibited the growth of LNCaP Par X1.6 tumors but was ineffective against G-R3 X1.2 tumors. PMC9019088

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.08mL

0.42mL

0.21mL

10.41mL

2.08mL

1.04mL

20.82mL

4.16mL

2.08mL

References

 

Historical Records

Categories